We then evaluated BORIS expression in a panel of 58 primary breast tumours, which consisted of tumours with different phenotypes: five ductal carcinomas in situ (DCIS), eight invasive adenocarcinomas (IAC), 33 invasive ductal carcinomas (IDC), seven invasive lobular carcinomas (ILC), three tumours with mixed phenotypes (MIXED) and two mucinous carcinomas (MUC CA). This evidence concerns the gene CTCFL and ductal breast carcinoma in situ.